Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Predrainage administration of Dopamine in the Renal function of selected patients with Obstructive Jaundice
ISRCTN ISRCTN14198655
ClinicalTrials.gov identifier
Public title Predrainage administration of Dopamine in the Renal function of selected patients with Obstructive Jaundice
Scientific title Predrainage administration of dopamine associated with fluid administration improved renal function in selected patients with obstructive jaundice: a prospective randomised study
Acronym DROJ
Serial number at source N/A
Study hypothesis No studies have been carried out to evaluate the effects of dopamine in obstructive jaundice (OJ) patients on the renal and endocrine derangements observed in these patients before biliary drainage or surgery. The present study was therefore designed to analyse the effect of dopamine associated with fluid administration on extracellular water (ECW), water and sodium regulating hormones and renal function alterations in patients with OJ undergoing endoscopic internal biliary drainage.
Lay summary
Ethics approval Hospital Reina Sofia Clinical Trials and Ethics Committee approved in March 2005 (ref: PIO-20155)
Study design Prospective randomised controlled study
Countries of recruitment Spain
Disease/condition/study domain Obstructive jaundice
Participants - inclusion criteria 1. Malignant OJ with serum bilirubin higher than 6 mg/dl
2. Ultrasound evidence of extrahepatic and intrahepatic bile duct dilation (more than 8 mm and 4 mm respectively)
3. Feasibility of internal endoscopic biliary drainage
4. Aged 35 to 76 years, either sex
Participants - exclusion criteria 1. Cholangitis
2. Acute pancreatitis
3. Heart disease
4. Arterial hypertension
5. Chronic lung disease
6. Use of diuretics
7. Chronic renal failure
Anticipated start date 10/01/2007
Anticipated end date 21/06/2009
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 100
Interventions Two treatment groups were created according to whether patients received dopamine at 3 mg/Kg/min or not, associated with 3000 ml of saline solution for 48 hours before biliary drainage in addition to their regular hospital ward diet. For the post-drainage study, patients treated with dopamine prior to biliary drainage, will be randomised according to whether they continue with dopamine for 72 hours or not. All patients will be kept under the same conditions. After endoscopic internal drainage, patients will fast for the first 12 hours and 2500 ml of glucosaline solution containing 150 mEq of NaCl will be administrated until the following morning. On the second day, the intravenous infusion will be stopped and patients will receive a 2000 kcal/day diet for up to 72 hours when the study protocol will finish. Billiary drainage is considered successful if total bilirubin decreases by at least 30% and aerobilia with reduction of the common bile duct diameter demonstrated by ultrasound 72 hours after the procedure.
Primary outcome measure(s) Renal function (CrCl), assessed at admission, before drainage, as well as 24 hours and 72 hours after biliary drainage.
Secondary outcome measure(s) Assessed at admission, before drainage, as well as 24 hours and 72 hours after biliary drainage:
1. Extracellular water (ECW) volume
2. Serum leves of aldosterone, renin, atrial natriuretic peptide (ANP), antidiuretic hormone (ADH), endothelin-1 (ET-1)
3. Urine prostaglandin E2 (PgE2)
Sources of funding Spanish Ministry of Health (Spain) - Health Research Fund (Fondo de Investigaciones Sanitarias [FIS]) (ref: PIO-20155)
Trial website
Publications
Contact name Prof  Javier  Padillo
  Address Imperio Argentina 43
  City/town Cordoba
  Zip/Postcode 14014
  Country Spain
Sponsor Reina Sofia University Hospital (Spain)
  Address Avda. Menéndez Pidal S/N
  City/town Cordoba
  Zip/Postcode 14004
  Country Spain
  Sponsor website: http://www.juntadeandalucia.es/servicioandaluzdesalud/hrs2/
Date applied 08/01/2010
Last edited 15/01/2010
Date ISRCTN assigned 15/01/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central